Nonclassical antifolates, part 4. 5-(2-Aminothiazol-4-yl)-4-phenyl-4H-1,2, 4-triazole-3-thiols as a new class of DHFR inhibitors: Synthesis, biological evaluation and molecular modeling study

European Journal of Medicinal Chemistry

Volumn 66, Issue , 2013, Pages 135-145

  Hassan, Ghada S ^a,b   El Messery, Shahenda M ^b   Al Omary, Fatmah A M ^a   Al Rashood, Sarah T ^a   Shabayek, Marwa I ^c   Abulfadl, Yasmin S ^c   Habib, El Sayed E ^d   El Hallouty, Salwa M ^e   Fayad, Walid ^e   Mohamed, Khaled M ^e   El Menshawi, Bassem S ^c   El Subbagh, Hussein I ^c  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b University of Mansoura   (Egypt)

^c FUTURE UNIVERSITY IN EGYPT   (Egypt)

^d TAIBAH UNIVERSITY   (Saudi Arabia)

^e NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

DHFR inhibitors; Molecular modeling study; Substituted thiazoles; Synthesis

Indexed keywords

AMINO ACID; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTISCHISTOSOMAL AGENT; CIPROFLOXACIN; DIHYDROFOLATE REDUCTASE INHIBITOR; DOXORUBICIN; FOLIC ACID ANTAGONIST; GENTAMICIN; METHOTREXATE; PRAZIQUANTEL; 5 (2 AMINOTHIAZOL 4 YL) 4 PHENYL 4H 1,2,4 TRIAZOLE 3 THIOL; ACETAMIDE DERIVATIVE; DIHYDROFOLATE REDUCTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MALE; MOLECULAR MODEL; NONHUMAN; DRUG DESIGN; ENZYME BINDING; STRUCTURE ACTIVITY RELATION;

EID: 84879228665     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.05.039     Document Type: Article

References (61)

1. R. Blakley, Eukaryotic dihydrofolate reductase, Adv. Enzymol. Relat. Areas Mol. Biol. 70 (1995) 23-102. (Pubitemid 3023037)
2. R. Ferone, Folate metabolism in malaria, Bull. World Health Organ. 55 (1977) 291-298. (Pubitemid 8234199)
3. H. Huang, W. Lu, X. Li, X. Cong, H. Ma, X. Liu, Y. Zhang, P. Che, R. Ma, H. Li, X. Shen, H. Jiang, J. Huang, Y. Zhang, J. Zhu, Design and synthesis of small molecular dual inhibitor of falcipain-2 and dihydrofolate reductase as antimalarial agent, Bioorg. Med. Chem. Lett. 22 (2012) 958-962.
4. F.M. Sirotnak, Folate Antagonists as Therapeutic Agents, John Wiley and Sons, New York, 1984.
5. I.M. Kompis, K. Islam, R.L. Then, DNA and RNA synthesis: antifolates, Chem. Rev. 105 (2005) 593-620. (Pubitemid 40351635)
6. J.M. Blaney, C. Hansch, C. Silipo, A. Vittoria, Structure-activity relationships of dihydrofolate reductase inhibitors, Chem. Rev. 84 (1984) 333-407. (Pubitemid 15184721)
7. V. Cody, S.F. Zakrzewski, Molecular structures of 2,4-diaminopyrimidine antifolates with antineoplastic activity, J. Med. Chem. 25 (1982) 427-430. (Pubitemid 12078647)
8. The World Health Report 2008, World Health Organization, Geneva, Switzerland, 2008. http://www.who.int/whr/2008/whr08-en.pdf.
9. A.R. Renslo, J.H. McKerrow, Drug discovery and development for neglected parasitic diseases, Nat. Chem. Biol. 2 (2006) 701-710. (Pubitemid 44764212)
10. A. Kleemann, J. Engel, Pharmaceutical Substances: Syntheses, Patents and Applications, fourth ed., Thieme Stuttgart, New York, 2001.
11. G.W.A. Milne, in: Ashgate (Ed.), Handbook of Antineoplastic Agents, Gower, London, UK, 2000.
12. M. Popsavin, S. Spaić, M. Svircev, V. Kojić, G. Bogdanović, V. Popsavin, Synthesis and antitumour activity of new tiazofurin analogues bearing a 2,3-anhydro functionality in the furanose ring, Bioorg. Med. Chem. Lett. 17 (2007) 4123-4127. (Pubitemid 47023150)
13. F.E. Wolter, L. Molinari, E.R. Socher, K. Schneider, G. Nicholson, W. Beil, O. Seitz, R.D. Süssmuth, Synthesis and evaluation of a netropsin-proximicin-hybrid library for DNA binding and cytotoxicity, Bioorg. Med. Chem. Lett. 19 (2009) 3811-3815.
14. S.M. Nelson, L.R. Ferguson, W.A. Denny, Non-covalent ligand/DNA interactions: minor groove binding agents, Mutat. Res. 623 (2007) 24-40. (Pubitemid 47376733)
15. B. Plouvier, R. Houssin, N. Helbecque, P. Colson, C. Houssier, J.P. Hénichart, C. Bailly, Influence of the methyl substituents of a thiazole-containing lexitropsin on the mode of binding to DNA, Anti-Cancer Drug Des. 10 (1995) 155-166.
16. M.B. Gravestock, M. Barry, EU Patent EP 94,146 B1, 1984.
17. T. Ikeda, K. Tada, EU Patent EP 2,62,589 B1, 1988.
18. G.T. Zitouni, Z.A. Kaplancikli, M.T. Yildiz, P. Chevallet, D. Kaya, Synthesis and antimicrobial activity of 4-phenyl/cyclohexyl-5-(1-phenoxyethyl)- 3-[N-(2-thiazolyl) acetamido]thio-4H-1,2,4-triazole derivatives, Eur. J. Med. Chem. 40 (2005) 607-613. (Pubitemid 40732529)
19. K. Walczak, A. Gondela, J. Suwin'ski, Synthesis and anti-tuberculosis activity of N-aryl-C-nitroazoles, Eur. J. Med. Chem. 39 (2004) 849-853. (Pubitemid 39298441)
20. B.S. Holla, K.N. Poojary, B.S. Rao, M.K. Shivananda, New bis-aminomercaptotriazoles and bis-triazolothiadiazoles as possible anticancer agents, Eur. J. Med. Chem. 37 (2002) 511-517. (Pubitemid 35245174)
21. B.S. Holla, B. Veerendra, M.K. Shivananda, B. Poojary, Synthesis characterization and anticancer activity studies on some Mannich bases derived from 1,2,4-triazoles, Eur. J. Med. Chem. 38 (2003) 759-767. (Pubitemid 36976785)
22. P. Gahtori, S.K. Ghosh, P. Parida, A. Prakash, K. Gogoi, U.P. Singh, H.R. Bhat, Antimalarial evaluation and docking studies of hybrid phenylthiazolyl-1,3,5-triazine derivatives: a novel and potential antifolate lead for Pf-DHFR-TS inhibition, Exp. Parasitol. 130 (2012) 292-299.
23. P. Gahtori, A. Singh, S.K. Ghosh, A. Das, U. Archana, Synthesis of some substituted phenylthiazolyl 1,3,5-triazine derivatives, Asian J. Chem. 23 (2011) 1189-1192.
24. S.T. Al-Rashood, I.A. Aboldahab, L.A. Abouzeid, A.A.-M. Abdel-Aziz, M.N. Nagi, S.G. Abdul-hamide, K.M. Youssef, A.M. Al-Obaid, H.I. El-Subbagh, Synthesis, dihydrofolate reductase inhibition, and molecular modeling study of some new 4(3H)-quinazolinone analogues, Bioorg. Med. Chem. 14 (2006) 8608-8621. (Pubitemid 44667527)
25. F.A.M. Al-Omary, L.A. Abou-zeid, M.N. Nagi, E.E. Habib, A.A.-M. Abdel-Aziz, A.S. El-Azab, S.G. Abdel-Hamide, M.A. Al-Omar, A.M. Al-Obaid, H.I. El-Subbagh, Non-classical antifolates. Part 2: synthesis, biological evaluation, and molecular modeling study of some new 2,6-substituted-quinazolin-4-ones, Bioorg. Med. Chem. 18 (2010) 2849-2863.
26. F.A.M. Al-Omary, G.S. Hassan, S.M. El-Messery, M.N. Nagi, E.E. Habib, H.I. El-Subbagh, Nonclassical antifolates, Part 3: synthesis, biological evaluation and molecular modeling study of some new 2-heteroarylthio-quinazolin- 4-ones, Eur. J. Med. Chem. 63 (2013) 33-45.
27. H.I. El-Subbagh, W.A. El-Naggar, F.A. Badria, Synthesis and biological testing of 2,4-disubstituted thiazole derivatives as potential antitumor antibiotics, Med. Chem. Res. 3 (1994) 503-516.
28. H.I. El-Subbagh, A.M. Al-Obaid, 2,4-disubstituted thiazoles, II. A novel class of antitumor agents, synthesis and biological evaluation, Eur. J. Med. Chem. 31 (1996) 1017-1021. (Pubitemid 26418446)
29. H.I. El-Subbagh, A.H. Abadi, J. Lehmann, 2,4-disustituted thiazoles, III. Synthesis and antitumor activity of ethyl 2-substituted-aminothiazole-4- carboxylate analogs, Arch. Pharm. Pharm. Med. Chem. 332 (1999) 137-142. (Pubitemid 29190037)
30. H.I. El-Subbagh, I.E. Al-Khawad, E.R. El-Bendary, A.M. Al-Obaid, Substituted thiazoles IV. Synthesis and antitumor activity of new substituted imidazo[2,1-b]thiazole analogs, Saudi Pharm. J. 9 (2001) 14-20. (Pubitemid 32520415)
31. F.A. Al-Omary, G.S. Hassan, S.M. El-Messery, H.I. El-Subbagh, Substituted thiazoles V. Synthesis and antitumor activity of novel thiazolo[2,3-b] quinazoline and pyrido[4,3-d]thiazolo[3,2-a]pyrimidine analogues, Eur. J. Med. Chem. 47 (2012) 65-72.
32. S.M. El-Messery, G.S. Hassan, F.A. Al-Omary, H.I. El-Subbagh, Substituted thiazoles VI. Synthesis and antitumor activity of new 2-acetamido- and 2 or 3-propanamido-thiazole analogs, Eur. J. Med. Chem. 54 (2012) 615-625.
33. G.S. Hassan, S.M. El-Messery, F.A. Al-Omary, H.I. El-Subbagh, Substituted thiazoles VII. Synthesis and antitumor activity of certain 2-(substituted amino)-4-phenyl-1,3-thiazole analogs, Bioorg. Med. Chem. Lett. 22 (2012) 6318-6323.
34. M.R. Grever, S.A. Schepartz, B.A. Chabner, The National Cancer Institute cancer drug discovery and development program, Semin. Oncol. 19 (1992) 622-638. (Pubitemid 23004840)
35. A. Monks, D. Scudiero, P. Skehan, R. Shoemaker, K. Paull, D. Vistica, C. Hose, J. Langley, P. Cronise, A. Vaigro-Wolff, M. Gray-Goodrich, H. Campbell, J. Mayo, M. Boyd, Feasibility of a high flux anticancer drug screen utilizing a derive panel of human tumor cell lines in culture, J. Natl. Cancer Inst. 83 (1991) 757-766.
36. M.R. Boyd, K.D. Paull, Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen, Drug Rev. Res. 34 (1995) 91-109.
37. B.S. El-Menshawi, W. Fayad, K. Mahmoud, S.M. El-Hallouty, M. El-Manawaty, M.H. Olofsson, S. Linder, Screening of natural products for therapeutic activity against solid tumors, Indian J. Exp. Biol. 48 (2010) 258-264.
38. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J.R. Warren, H. Bokesch, S. Kenney, M.R. Boyd, New colorimetric cytotoxicity assay for anticancer-drug screening, J. Natl. Cancer Inst. 82 (1990) 1107-1112. (Pubitemid 20213250)
39. B. Plouvier, R. Houssin, C. Bailly, J. Heinchart, Synthesis and DNA-binding study of a thiazole-containing analog of netropsin, J. Heterocyclic Chem. 26 (1989) 1643-1647. (Pubitemid 20092546)
40. N. Blank, W. Ditullio, F.F. Owings, L. Deviney, C.K. Miao, H.L. Saunders, Mercapto heterocyclic carboxylic acids, analogs of 3-mercaptopicolinic acid, J. Med. Chem. 20 (1977) 572-576. (Pubitemid 8065717)
41. C.A. Lipinski, J.L. Lamattina, P.J. Oates, Bioisosteric prototype design of biaryl imidazolyl and triazolyl competitive histamine H2-receptor antagonists, J. Med. Chem. 29 (1986) 2154-2163. (Pubitemid 17182287)
42. 2 in rhesus monkeys, J. Clin. Oncol. 10 (1992) 1359-1364.
43. C. Falk, R. Clark, M. Kalman, Enzymatic assay for methotrexate in serum and cerebrospinal fluid, Clin. Chem. 22 (1976) 785-788.
44. R. Pignatello, G. Sapmpinato, V. Sorrenti, L. Vicari, C. Di-Giacomo, A. Vanella, G. Puglisi, Aliphatic α,γ-bis(amides) of methotrexate. Influence of chain length on in vitro activity against sensitive and resistant tumour cells, Pharm. Pharmacol. Commun. 5 (1999) 299-305. (Pubitemid 29245831)
45. CLSI approved standards M100-S15Performance Standards for Antimicrobial Susceptibility Testing, Clinical and Laboratory Standards Institute (CLSI), Wayne, PA, 2008.
46. P.R. Murray, E.J. Baron, M.A. Pfaller, F.C. Tenover, R.H. Yolken, in: G.L. Wood, J.A. Washington (Eds.), Manual of Clinical Microbiology, American Society for Microbiology, Washington D.C, 1995.
47. M.I. Thabrew, R.D. Hughes, I.G. McFarlane, Screening of hepatoprotective plant components using a HepG2 cell cytotoxicity assay, J. Pharm. Pharmacol. 49 (1997) 1132-1135. (Pubitemid 27496730)
48. T. Mosmann, Rapid colorimetric assays for cellular growth and survival: application to proliferation and cytotoxicity assays, J. Immunol. Methods 65 (1983) 55-63. (Pubitemid 14203433)
49. F. Yousif, M.S. Hifnawy, G. Soliman, L. Boulos, T. Labib, F. Ramzy, M. Yousif, I. Hassan, K. Mahmoud, S.M. El-Hallouty, S. Mahmoud, M. El-Gendy, L. Gohar, M. El-Manawaty, W. Fayyad, B.S. El-Menshawi, Large-scale in vitro screening of Egyptian native and cultivated plants for schistosomicidal activity, Pharm. Biol. 45 (2007) 501-510. (Pubitemid 47123966)
50. F. Yousif, G. Wassel, L. Boulos, T. Labib, K. Mahmoud, S. El-Hallouty, S. El Bardicy, S. Mahmoud, F. Ramzy, L. Gohar, M. El-Manawaty, M.A. El Gendy, W. Fayad, B. El-Menshawi, Contribution to in vitro screening of Egyptian plants for schistosomicidal activity, Pharm. Biol. 50 (2012) 732-739.
51. J.R. Appleman, W.A. Beard, T.J. Delcamp, N.J. Prendergast, J.H. Freisheim, R.L. Blakley, Kinetics of the formation and isomerization of methotrexate complexes of recombinant human dihydrofolate reductase, J. Biol. Chem. 263 (1988) 10304-10313.
52. R.L. Blakley, L. Cocco, Role of isomerization of initial complexes in the binding of inhibitors to dihydrofolate reductase, Biochemistry 24 (1985) 4772-4777. (Pubitemid 16215812)
53. J.F. Davies, T.J. Delcamp, N.J. Prendergast, V.A. Ashford, J.H. Freisheim, J. Kraut, Crystal structures of recombinant human dihydrofolate reductase complexed with folate and 5-deazafolate, Biochemistry 29 (1990) 9467-9479. (Pubitemid 20329084)
54. C. Oefner, A. D'Arcy, F.K. Winkle, Crystal structure of human dihydrofolate reductase complexed with folate, Eur. J. Biochem. 174 (1988) 377-385.
55. B.J. Stockman, N.R. Nirmala, G. Wagner, T.J. Delcamp, M.T. DeYarman, J.H. Freisheim, Methotrexate binds in a non-productive orientation to human dihydrofolate reductase in solution based on NMR spectroscopy, FEBS Lett. 283 (1991) 267-269.
56. M. Feher, E. Sourial, J.M. Schmidt, P. Labute, et al., Flexible alignment of small molecules, J. Med. Chem. 44 (2001) 1483-1490. (Pubitemid 32852192)
57. V. Cody, C.H. Schwalbe, Structural characteristics of antifolate dihydrofolate reductase enzyme interactions, Crystallogr. Rev. 12 (2006) 301-333. (Pubitemid 350067133)
58. J.P. Volpato, B.J. Yachnin, J. Blanchet, V. Guerrero, L. Poulin, E.A. Fossati, M. Berghuis, J.N. Pelletier, Multiple conformers in active site of human dihydrofolate reductase F31R/Q35E double mutant suggest structural basis for methotrexate resistance, J. Biol. Chem. 284 (2009) 20079-20089.
59. S. Profeta, N.L. Allinger, Molecular mechanics calculations on aliphatic amines, J. Am. Chem. Soc. 107 (1985) 1907-1918.
60. N.L. Allinger, Conformational analysis. 130. MM2. A hydrocarbon force field utilizing V1 and V2 torsional terms, J. Am. Chem. Soc. 99 (1977) 8127-8134.
61. S. Kearsley, G.M. Smith, An alternative method for the alignment of molecular structures: maximizing electrostatic and steric overlap, Tetrahedron Comput. Methodol. 3 (1990) 615-633.